Belpointe Asset Management LLC Takes Position in Becton, Dickinson and Company $BDX

Belpointe Asset Management LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 3,473 shares of the medical instruments supplier’s stock, valued at approximately $650,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC raised its stake in Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares in the last quarter. PFG Investments LLC lifted its position in Becton, Dickinson and Company by 32.7% in the second quarter. PFG Investments LLC now owns 2,601 shares of the medical instruments supplier’s stock valued at $448,000 after acquiring an additional 641 shares during the last quarter. Trilogy Capital Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $238,000. Finally, USA Financial Formulas boosted its holdings in shares of Becton, Dickinson and Company by 10.8% in the second quarter. USA Financial Formulas now owns 934 shares of the medical instruments supplier’s stock valued at $161,000 after acquiring an additional 91 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BDX. Bank of America increased their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Royal Bank Of Canada lifted their price objective on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a report on Wednesday, December 17th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $209.00.

Becton, Dickinson and Company Price Performance

BDX opened at $203.56 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The stock has a market capitalization of $58.00 billion, a PE ratio of 34.92, a P/E/G ratio of 2.22 and a beta of 0.23. The company’s 50 day simple moving average is $198.54 and its 200 day simple moving average is $191.24. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. The firm had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 2,680 shares of company stock worth $539,848 over the last three months. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.